| Abstract: | The Food and Drug Administration (FDA) approved Glaxo Wellcome's nucleoside analog, abacavir (Ziagen, formerly 1592), for combination anti-HIV regimens for adults and children. In an early trial, abacavir was effective in suppressing HIV replication in combination with other antiretroviral drugs. Abacavir is generally well-tolerated, with minimal side effects. People who experience severe side effects within six weeks after starting abacavir should contact their doctor immediately. If medication is stopped due to severe hypersensitivity, it should not be restarted because it could result in a life-threatening reaction. |
